TFX vs XRAY Stock Comparison
Compare TFX and XRAY across AIQ Score, fundamentals, valuation, momentum, risk, analyst expectations and current market evidence.
What is the main difference between TFX and XRAY?
TFX leads the current stock comparison as Teleflex Incorporated, with the clearest separation coming from risk resilience and the broader AIQ evidence mix.
AlgovestIQ AIQ Comparison
Teleflex Incorporated vs DENTSPLY SIRONA Inc.
TFX leads
TFX leads by 3 AIQ points, primarily on Risk Resilience and Quality, but the lead has narrowed from 14 points over 30 sessions. Wall Street currently favors XRAY on target upside.
Fragile: 3 of 6 evidence groups support TFX, its lead is narrowing, and its current signal state is conflicted.
Teleflex Incorporated
DENTSPLY SIRONA Inc.
The Algovestiq AIQ Score currently favors TFX over XRAY, 50 versus 47 as of Sep 11, 2026. TFX's advantage is driven primarily by stronger risk resilience and quality, while XRAY holds the stronger value profile. TFX also shows the stronger technical structure relative to its 50-day moving average, though analyst target upside currently favors XRAY. 3 of 6 covered evidence groups favor TFX today, and the comparison is rated Fragile on stability: the AIQ gap is narrow at 3 points. TFX lead: Weakening — the AIQ differential moved from 14 to 3 points over 30 sessions.
Compare Teleflex Incorporated and DENTSPLY SIRONA Inc. across the Algovestiq AIQ Score, valuation, quality, momentum, risk, technicals and analyst expectations.
Performance over time
Price-return comparison using available daily close history.
Total return comparison
Growth of $10,000
Based on available close-price history. Distribution reinvestment is not added unless already reflected in the source series.
Compare TFX and XRAY against another ticker
Open a multi-ticker workspace without changing this focused pair page.
AIQ Factor Divergence
Where the two separate, on the four dimensions behind the AIQ Score. Bars read outward from a shared zero: further from the centre is a wider gap.
- Risk Resilience64 vs 50TFX +14
- Quality39 vs 27TFX +12
- Value62 vs 73XRAY +11
- Momentum41 vs 37TFX +4
3 of 6 evidence groups favor TFX. TFX’s edge is concentrated in risk resilience and quality; XRAY keeps a meaningful value edge.
What changed since the last close
Latest scored session 2026-09-10, compared against the prior scored session 2026-09-09.
Largest factor move: Momentum -19
No new signals fired.
No factor moved materially.
No new signals fired.
TFX's lead narrowed by 5 AIQ points in the latest snapshot.
Deeper signal detail for each name lives on its own signals page — TFX and XRAY both carry a full feed there.
The central trade-off
TFX (Teleflex Incorporated): the stronger current systematic profile, led by risk resilience and quality.
XRAY (DENTSPLY SIRONA Inc.): the counter-case, on value, valuation, analyst expectations — but at materially higher volatility, 33.1% against 25.4%.
The AIQ Score and Wall Street therefore point in different directions on this pair.
Which one fits your objective
The same two names rank differently depending on what you are optimizing for. All six reads are shown at once — none of them is hidden behind a toggle.
Balanced
TFXTFX on the overall AIQ Score, which weights Quality and Value most heavily.
Growth
TFXTFX on combined revenue and EPS growth.
Value
XRAYXRAY on the peer-relative Value factor, by 11 points.
Momentum
TFXTFX on the Momentum factor, by 4 points.
Lower downside
TFXTFX on Risk Resilience, by 14 points.
Analyst upside
XRAYXRAY on implied upside to the consensus price target.
AIQ vs Wall Street
The model and the Street disagree here: AIQ favors TFX, analyst targets favor XRAY. That disagreement is the most useful thing on this page.
| Measure | TFX | XRAY | Note |
|---|---|---|---|
| Implied upside to target | +16.2% | +24.3% | XRAY has more room |
| Target dispersion | +27.6% | +61.5% | Lower is tighter analyst agreement |
| Consensus | Buy | Hold | Context, not a primary driver |
| Analysts covering | 8 | 5 | Higher coverage generally improves confidence |
The two are measuring different things. The AIQ Score reads current fundamentals, valuation, trend and risk; analyst targets price forward expectations. A divergence of this kind is either a contrarian opportunity or a sign the model is missing something already priced in — it is worth resolving before acting on either.
Analyst targets are expectations, not predictions. Dispersion matters as much as the midpoint.
AIQ Agreement Matrix
3 of 6 covered evidence groups favor TFX. A wide gap backed by one group is a weaker case than a narrow gap backed by five.
| Evidence group | Favors | Reading |
|---|---|---|
| AIQ Score | Even | 50 vs 47 |
| Fundamentals | TFXon balance | revenue growth 4% vs 2%; EPS growth 13.7% vs 4.6%; TTM ROE -31.8% vs -39.8%; gross margin 53.8% vs 49.5%; operating margin 3.3% vs 11.7% — TFX takes 4 of 5 decided legs, not all of them |
| Valuation | XRAY | Value 62 vs 73 |
| Technicals | TFX | Price vs 50-day -3.4% vs -13.9%; vs 200-day 6.8% vs -10.6% |
| Risk Resilience | TFX | Risk Resilience 64 vs 50 |
| Analyst expectations | XRAY | Target upside 16.2% vs 24.3% |
✓ agrees with the overall verdict · ✕ points the other way. Groups marked “not covered” lack data on one or both of TFX and XRAY and are excluded from the count.
AIQ Decision Stability
The conclusion is sensitive to small changes. Treat the lead as provisional and watch the flip conditions below.
- The AIQ gap is narrow at 3 points. (argues the conclusion is provisional)
- Only 3 of 6 covered evidence groups agree. (argues the conclusion is provisional)
- The leader's advantage has been narrowing. (argues the conclusion is provisional)
- The leader is throwing conflicting signals. (argues the conclusion is provisional)
Stability combines the score gap, how broadly the evidence agrees, how steady the lead has been across daily snapshots, the current signal state on both names, and analyst dispersion on TFX.
How the comparison changed
119 daily snapshots · May 4 – Sep 10TFX lead: Weakening — the AIQ differential moved from 14 to 3 points over 30 sessions.
- Today
- TFX +3
- 50 vs 47
- 7 sessions ago
- TFX +9
- 58 vs 49
- 30 sessions ago
- TFX +14
- 56 vs 42
- 90 sessions ago
- Level
- 57 vs 57
The lead changed hands 5 times in this window, most recently on Jul 31 when TFX moved ahead of XRAY.
AIQ Signal Divergence
Only the signals that bear on the head-to-head. A conflicted name is carrying bullish and bearish rules at the same time — the technical evidence is not pointing one way.
2 bullish / 1 bearish, conflicted
- Golden Cross Active — bullish, trend, long horizon (9.73%)
- EMA Ribbon Expansion Bullish — bullish, trend, medium horizon
- MACD Bearish Crossover — bearish, momentum, short horizon
2 bullish / 0 bearish / 2 neutral
- Golden Cross Active — bullish, trend, long horizon (3.42%)
- Bollinger Band Squeeze — neutral, volatility, short horizon
- ATR Expansion - Breakout Mode — neutral, volatility, short horizon (4.53%)
TFX leads the comparison while carrying a conflicted signal state, which is one reason the stability rating is not higher.
Price vs model alignment
Whether the latest session's price move confirms what the model did over the same session, or contradicts it.
Price and the AIQ Score both moved down over the latest session (price -0.77%, AIQ -5 points).
Neither the price nor the AIQ Score moved enough in the latest session to confirm or contradict the other (price -0.38%, AIQ 0 points).
What would flip this result
A state, not a forecast. These are the specific, observable changes that would reverse the verdict — not a price prediction.
- 1XRAY closes the Risk Resilience gap — currently 14 points behind, the largest single contributor to TFX's edge.
- 2XRAY's Bollinger Band Squeeze turns directional — it is neutral today and would confirm a change in trend.
- 3TFX's conflicting signal state resolves bearish — it currently carries 2 bullish and 1 bearish rules at once.
- 4The narrowing continues — the lead has already given back 11 points over 30 sessions, and a further 3-point move would eliminate TFX's advantage entirely.
The full evidence
Every number behind the verdict. The leader is called above each group so you are not left to solve it from the table.
Fundamentals
TFX leads on balance| Metric | TFX | XRAY |
|---|---|---|
| Revenue growth (YoY) | 4% | 2% |
| EPS growth (YoY) | 13.7% | 4.6% |
| Gross margin | 53.8% | 49.5% |
| Operating margin | 3.3% | 11.7% |
| Return on equity (TTM) | -31.8% | -39.8% |
| Debt to equity | 0.99 | 1.71 |
Performance
TFX leads 5 of 6 windows| Metric | TFX | XRAY |
|---|---|---|
| 1 week (5 sessions) | -6.4% | -7% |
| 1 month (20 sessions) | -3.2% | -8% |
| 3 months (63 sessions) | -0.1% | 4.6% |
| 6 months (126 sessions) | 18.1% | -17.5% |
| Year to date | 8.2% | -8.1% |
| 1 year (252 sessions) | 2.6% | -26.1% |
Technicals
TFX has the stronger structure| Metric | TFX | XRAY |
|---|---|---|
| RSI (14) | 43.9 | 44.5 |
| ADX (14) | 12.1 | 20.8 |
| Price vs 50-day | -3.4% | -13.9% |
| Price vs 200-day | 6.8% | -10.6% |
| Volatility (1M, annualized) | 25.4% | 33.1% |
Risk
TFX is the more resilient| Metric | TFX | XRAY |
|---|---|---|
| Beta | 0.76 | 1.3 |
| Sharpe ratio | 0.14 | -0.46 |
| Sortino ratio | 0.19 | -0.73 |
| Max drawdown | -24.6% | -34.3% |
| Current drawdown | -7.1% | -28.5% |
| Annualized volatility | 40.4% | 46.4% |
| Value at risk (95%) | -3.1% | -4.2% |
Straight answers
Each answer is regenerated from the current snapshot, not written once and left to age.
Which is better, TFX or XRAY?
On the Algovestiq AIQ Score, TFX is the stronger of the two as of Sep 11, 2026, scoring 50 against XRAY's 47. The edge comes from risk resilience and quality. XRAY is not without a case — it holds the better value profile, which matters more if that is the objective you are optimizing for. This is a systematic score, not a recommendation: it ranks the two on the same evidence, it does not know your holding period or tax position.
Is TFX or XRAY the better buy right now?
TFX carries the stronger systematic profile as of Sep 11, 2026, and the comparison is rated Fragile — 3 of 6 covered evidence groups agree. A Fragile rating means the conclusion is sensitive: the AIQ gap is narrow at 3 points. Treat the lead as provisional.
Why does the AIQ Score favor TFX over XRAY?
The composite weights Quality, Value, Momentum and Risk Resilience. TFX leads Risk Resilience by 14 points; TFX leads Quality by 12 points; XRAY leads Value by 11 points. Where the two split, the factor with the larger weight carries the result.
Which has more analyst upside, TFX or XRAY?
Analyst price targets imply +16.2% upside for TFX and +24.3% for XRAY, so the Street currently favors XRAY. That points the opposite way to the AIQ Score, which favors TFX. The two are measuring different things: the model reads current fundamentals, valuation, trend and risk; the Street is pricing forward expectations. A divergence of this kind is either a contrarian opportunity or a sign the model is missing something the analysts have already priced — it is the single most useful row on this page to investigate. Analyst targets are expectations, not predictions, and dispersion matters as much as the midpoint.
Which is better value, TFX or XRAY?
XRAY is the better-valued of the two on the peer-relative Value factor. XRAY on the peer-relative Value factor, by 11 points. The Value factor reads valuation relative to sector peers and to the company's own fundamental quality, so it is not the same as simply having the lower multiple.
Which has stronger growth, TFX or XRAY?
TFX on combined revenue and EPS growth. Growth here is measured on reported revenue and earnings, not on forward estimates — it describes what the businesses have delivered, not what the Street expects next.
Which has stronger momentum, TFX or XRAY?
TFX on the Momentum factor, by 4 points. Momentum is one of the four weighted factors in the AIQ composite. It has documented persistence over three- to twelve-month horizons, which makes it a timing input rather than a reason to hold something indefinitely.
Which is riskier, TFX or XRAY?
TFX is the more resilient of the two, so the other name carries the higher downside risk. TFX on Risk Resilience, by 14 points. Risk Resilience is a weighted factor in the composite; position sizing usually responds to it more usefully than the buy/avoid decision does.
Is TFX more profitable than XRAY?
The profitability evidence is mixed: gross margin 53.8% vs 49.5%; operating margin 3.3% vs 11.7%; ttm roe -31.8% vs -39.8%. TFX leads on two measures and XRAY on one measure, and there is no single profitability composite that resolves the split — which of the two reads as "more profitable" depends on whether you weight pricing power or operating leverage.
Is TFX's lead over XRAY getting stronger or weaker?
TFX lead: Weakening — the AIQ differential moved from 14 to 3 points over 30 sessions. This is measured from 119 daily comparison snapshots between 2026-05-04 and 2026-09-10. The lead has changed hands 5 times in that window, most recently on 2026-07-31, when TFX moved ahead of XRAY.
What would change the TFX vs XRAY verdict?
The result is a state, not a forecast, so it changes when the underlying evidence changes. Concretely: XRAY closes the Risk Resilience gap — currently 14 points behind, the largest single contributor to TFX's edge; XRAY's Bollinger Band Squeeze turns directional — it is neutral today and would confirm a change in trend; TFX's conflicting signal state resolves bearish — it currently carries 2 bullish and 1 bearish rules at once; the narrowing continues — the lead has already given back 11 points over 30 sessions, and a further 3-point move would eliminate TFX's advantage entirely.
What do the current signals say about TFX and XRAY?
TFX: 2 bullish / 1 bearish, conflicted. XRAY: 2 bullish / 0 bearish / 2 neutral. A conflicted state means bullish and bearish rules are active on the same name at once — the technical evidence is not pointing one way, and a decision taken on it carries more timing risk. The most decision-relevant rule on TFX is Golden Cross Active (bullish, long horizon). On XRAY it is Golden Cross Active (bullish, long horizon).
Compare TFX and XRAY with others
Continue your research
This page answers which of the two. These answer the questions on either side of it.
How this comparison is scored
The Algovestiq AIQ Score composites four factors — Quality, Value, Momentum and Risk, each carrying a fixed weight. Sentiment is reported separately as SentimentPulse and is not folded into the composite. Scores refresh every trading day, and this page regenerates from the latest snapshot rather than being written once.
The verdict names a leader, states how broadly six independent evidence groups agree, and rates how durable that conclusion is given the score gap, its recent trajectory and the current signal state on both names.
How to use side-by-side comparison →This comparison is informational and educational, not investment advice. AIQ scores update daily; re-check after earnings, guidance or macro data that materially changes either name’s factor profile.